Along with a host of other reasons, I would imagine that the infatuation with Ponatinib earlier lines had some correlation with Denner's attempt to remove Berger.
>>Run a large dose ranging trial at the same time as a large randomized trial in earlier line?
Agree, but that's not my only complaint. The whole idea of true 2nd-line is misguided at this point.
Much better to go after 2nd-gen failures (so call it 2.5-line). In other words 2nd-line if a 2nd-gen drug was used as front-line, otherwise 3rd-line. There they could very likely show convincing evidence, while a 1-year trial in true 2nd-line isn't going to convince anyone of long-term safety.
News 
Market Data 
Discover 
